Diabetes and its complications continue to have a major impact on the morbidity and mortality in both the developed and developing world. While the condition does have a gamut of options at the physician’s disposal such as insulin, metformin, GLP analogues, DPP-4 inhibitors and SGLT-2 inhibitors, each of these drugs are not without its own set of unique nuances. A significant proportion of patients do not achieve adequate glucose control.Lixisenatide is a novel GLP-1 agonist that is approved for the treatment of diabetes. The drug is given at a dose of 10 mcg once daily for 14 days via subcutaneous route using a pre-filled pen. Gastrointestinal intolerance is a common issue as seen with other GLP agonists. Efficacy with the drug has been modest and been shown to be non-inferior to other GLP agonists such as exenatide. The once daily dosing, low risk of hypoglycemia and the relative cost benefit may make it an attractive option for physicians to prescribe this molecule in patients with uncontrolled diabetes.